SEARCH

SEARCH BY CITATION

References

  • 1
    Golden, S.H., Robinson, K.A., Saldanha, I. et al. (2009) Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. Journal of Clinical Endocrinology and Metabolism, 94, 18531878.
  • 2
    Kebebew, E., Reiff, E., Duh, Q.Y. et al. (2006) Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World Journal of Surgery, 30, 872878.
  • 3
    Koschker, A.C., Fassnacht, M., Hahner, S. et al. (2006) Adrenocortical carcinoma – improving patient care by establishing new structures. Experimental and Clinical Endocrinology & Diabetes, 114, 4551.
  • 4
    Lehmann, T. & Wrzesinski, T. (2012) The molecular basis of adrenocortical cancer. Cancer Genetics, 205, 131137.
  • 5
    Sandrini, R., Ribeiro, R.C. & DeLacerda, L. (1997) Childhood adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism, 82, 20272031.
  • 6
    Ribeiro, R.C., Sandrini, F., Figueiredo, B. et al. (2001) An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 98, 93309335.
  • 7
    Pinto, E.M., Billerbeck, A.E., Villares, M.C. et al. (2004) Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. Arquivos Brasileiros De Endocrinologia E Metabologia 48, 647650.
  • 8
    Lorea, C.F., Moreno, D.A., Borges, K.S. et al. (2012) Expression profile of apoptosis-related genes in childhood adrenocortical tumors: low level of expression of BCL2 and TNF genes suggests a poor prognosis. European Journal of Endocrinology, 167, 199208.
  • 9
    Bertherat, J. & Bertagna, X. (2009) Pathogenesis of adrenocortical cancer. Best Practice and Research. Clinical Endocrinology and Metabolism, 23, 261271.
  • 10
    Luton, J.P., Cerdas, S., Billaud, L. et al. (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. New England Journal of Medicine, 322, 11951201.
  • 11
    Zini, L., Porpiglia, F. & Fassnacht, M. (2011) Contemporary management of adrenocortical carcinoma. European Urology, 60, 10551065.
  • 12
    Fassnacht, M., Libe, R., Kroiss, M. et al. (2011) Adrenocortical carcinoma: a clinician's update. Nature Reviews Endocrinology, 7, 323335.
  • 13
    Stojadinovic, A., Ghossein, R.A., Hoos, A. et al. (2002) Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. Journal of Clinical Oncology, 20, 941950.
  • 14
    Fassnacht, M. & Allolio, B. (2009) Clinical management of adrenocortical carcinoma. Best Practice and Research. Clinical Endocrinology and Metabolism, 23, 273289.
  • 15
    Icard, P., Goudet, P., Charpenay, C. et al. (2001) Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World Journal of Surgery, 25, 891897.
  • 16
    Allolio, B. & Fassnacht, M. (2006) Clinical review: adrenocortical carcinoma: clinical update. Journal of Clinical Endocrinology and Metabolism, 91, 20272037.
  • 17
    Schteingart, D.E., Doherty, G.M., Gauger, P.G. et al. (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocrine-Related Cancer, 12, 667680.
  • 18
    Berruti, A., Fassnacht, M., Baudin, E. et al. (2010) Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. Journal of Clinical Oncology, 28, e401e402; author reply e403.
  • 19
    Abiven, G., Coste, J., Groussin, L. et al. (2006) Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. Journal of Clinical Endocrinology and Metabolism, 91, 26502655.
  • 20
    Soon, P.S., McDonald, K.L., Robinson, B.G. et al. (2008) Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist, 13, 548561.
  • 21
    Raymond, V.M., Everett, J.N., Furtado, L.V. et al. (2013) Adrenocortical carcinoma is a lynch syndrome-associated cancer. Journal of Clinical Oncology, 31, 30123018.
  • 22
    de Fraipont, F., El Atifi, M., Cherradi, N. et al. (2005) Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. Journal of Clinical Endocrinology and Metabolism, 90, 18191829.
  • 23
    de Reynies, A., Assie, G., Rickman, D.S. et al. (2009) Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. Journal of Clinical Oncology, 27, 11081115.
  • 24
    Soon, P.S., Libe, R., Benn, D.E. et al. (2008) Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors. Annals of Surgery, 247, 157164.
  • 25
    Sidhu, S., Marsh, D.J., Theodosopoulos, G. et al. (2002) Comparative genomic hybridization analysis of adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism, 87, 34673474.
  • 26
    Barlaskar, F.M. & Hammer, G.D. (2007) The molecular genetics of adrenocortical carcinoma. Reviews in Endocrine & Metabolic Disorders, 8, 343348.
  • 27
    Hollstein, M., Sidransky, D., Vogelstein, B. et al. (1991) p53 mutations in human cancers. Science, 253, 4953.
  • 28
    Brosh, R. & Rotter, V. (2009) When mutants gain new powers: news from the mutant p53 field. Nature Reviews Cancer, 9, 701713.
  • 29
    Vogelstein, B., Lane, D. & Levine, A.J. (2000) Surfing the p53 network. Nature, 408, 307310.
  • 30
    Varley, J.M., McGown, G., Thorncroft, M. et al. (1999) Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. American Journal of Human Genetics, 65, 9951006.
  • 31
    Hisada, M., Garber, J.E., Fung, C.Y. et al. (1998) Multiple primary cancers in families with Li-Fraumeni syndrome. Journal of the National Cancer Institute, 90, 606611.
  • 32
    Malkin, D., Li, F.P., Strong, L.C. et al. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science, 250, 12331238.
  • 33
    Reincke, M., Karl, M., Travis, W.H. et al. (1994) p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. Journal of Clinical Endocrinology and Metabolism, 78, 790794.
  • 34
    Libe, R., Groussin, L., Tissier, F. et al. (2007) Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clinical Cancer Research, 13, 844850.
  • 35
    Wagner, J., Portwine, C., Rabin, K. et al. (1994) High frequency of germline p53 mutations in childhood adrenocortical cancer. Journal of the National Cancer Institute, 86, 17071710.
  • 36
    Ragazzon, B., Libe, R., Gaujoux, S. et al. (2010) Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Research, 70, 82768281.
  • 37
    DiGiammarino, E.L., Lee, A.S., Cadwell, C. et al. (2002) A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Natural Structural Biology, 9, 1216.
  • 38
    Latronico, A.C., Pinto, E.M., Domenice, S. et al. (2001) An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism, 86, 49704973.
  • 39
    Achatz, M.I., Olivier, M., Le Calvez, F. et al. (2007) The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Letters, 245, 96102.
  • 40
    Pinto, E.M., Billerbeck, A.E., Fragoso, M.C. et al. (2005) Deletion mapping of chromosome 17 in benign and malignant adrenocortical tumors associated with the Arg337His mutation of the p53 tumor suppressor protein. Journal of Clinical Endocrinology and Metabolism, 90, 29762981.
  • 41
    Gicquel, C., Bertagna, X., Gaston, V. et al. (2001) Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Research, 61, 67626767.
  • 42
    Maher, E.R. & Reik, W. (2000) Beckwith-Wiedemann syndrome: imprinting in clusters revisited. Journal of Clinical Investigation, 105, 247252.
  • 43
    Gicquel, C., Bertagna, X., Schneid, H. et al. (1994) Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism, 78, 14441453.
  • 44
    Gicquel, C., Raffin-Sanson, M.L., Gaston, V. et al. (1997) Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. Journal of Clinical Endocrinology and Metabolism, 82, 25592565.
  • 45
    Hoeflich, A., Reisinger, R., Lahm, H. et al. (2001) Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Research, 61, 86018610.
  • 46
    Samani, A.A., Yakar, S., LeRoith, D. et al. (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocrine Reviews, 28, 2047.
  • 47
    Boulle, N., Logie, A., Gicquel, C. et al. (1998) Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism, 83, 17131720.
  • 48
    Giordano, T.J., Thomas, D.G., Kuick, R. et al. (2003) Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. American Journal of Pathology, 162, 521531.
  • 49
    Weber, M.M., Auernhammer, C.J., Kiess, W. et al. (1997) Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands. European Journal of Endocrinology, 136, 296303.
  • 50
    Doghman, M., El Wakil, A., Cardinaud, B. et al. (2010) Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Research, 70, 46664675.
  • 51
    Almeida, M.Q., Fragoso, M.C., Lotfi, C.F. et al. (2008) Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism, 93, 35243531.
  • 52
    Barlaskar, F.M., Spalding, A.C., Heaton, J.H. et al. (2009) Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism, 94, 204212.
  • 53
    Maluf, D.F., de Oliveira, B.H. & Lalli, E. (2011) Therapy of adrenocortical cancer: present and future. American Journal of Cancer Research, 1, 222232.
  • 54
    Haluska, P., Worden, F., Olmos, D. et al. (2010) Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemotherapy and Pharmacology, 65, 765773.
  • 55
    Carden, C.P., Frentzas, S., Langham, M. et al. (2009) Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors. Journal of Clinical Oncology, 27.
  • 56
    Kim, A.C., Reuter, A.L., Zubair, M. et al. (2008) Targeted disruption of beta-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. Development, 135, 25932602.
  • 57
    Cadoret, A., Ovejero, C., Terris, B. et al. (2002) New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene, 21, 82938301.
  • 58
    El Wakil, A. & Lalli, E. (2011) The Wnt/beta-catenin pathway in adrenocortical development and cancer. Molecular and Cellular Endocrinology, 332, 3237.
  • 59
    Gaujoux, S., Tissier, F., Groussin, L. et al. (2008) Wnt/beta-catenin and 3′,5′-cyclic adenosine 5′-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism, 93, 41354140.
  • 60
    Tadjine, M., Lampron, A., Ouadi, L. et al. (2008) Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clinical Endocrinology, 68, 264270.
  • 61
    Tissier, F., Cavard, C., Groussin, L. et al. (2005) Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Research, 65, 76227627.
  • 62
    Berthon, A., Sahut-Barnola, I., Lambert-Langlais, S. et al. (2010) Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Human Molecular Genetics, 19, 15611576.
  • 63
    Forbes, S.A., Bhamra, G., Bamford, S. et al. (2008) The Catalogue of Somatic Mutations in Cancer (COSMIC). Current Protocols in Human Genetics Chapter 10, Unit 10 11.
  • 64
    Doghman, M., Cazareth, J. & Lalli, E. (2008) The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. Journal of Clinical Endocrinology and Metabolism, 93, 32223225.
  • 65
    Schimmer, B.P. & White, P.C. (2010) Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease. Molecular Endocrinology, 24, 13221337.
  • 66
    Lalli, E. (2010) Adrenocortical development and cancer: focus on SF-1. Journal of Molecular Endocrinology, 44, 301307.
  • 67
    Pianovski, M.A., Cavalli, L.R., Figueiredo, B.C. et al. (2006) SF-1 overexpression in childhood adrenocortical tumours. European Journal of Cancer, 42, 10401043.
  • 68
    Figueiredo, B.C., Cavalli, L.R., Pianovski, M.A. et al. (2005) Amplification of the steroidogenic factor 1 gene in childhood adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism, 90, 615619.
  • 69
    Almeida, M.Q., Soares, I.C., Ribeiro, T.C. et al. (2010) Steroidogenic factor 1 overexpression and gene amplification are more frequent in adrenocortical tumors from children than from adults. Journal of Clinical Endocrinology and Metabolism, 95, 14581462.
  • 70
    Doghman, M., Karpova, T., Rodrigues, G.A. et al. (2007) Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Molecular Endocrinology, 21, 29682987.
  • 71
    Lichtenauer, U.D., Duchniewicz, M., Kolanczyk, M. et al. (2007) Pre-B-cell transcription factor 1 and steroidogenic factor 1 synergistically regulate adrenocortical growth and steroidogenesis. Endocrinology, 148, 693704.
  • 72
    Sbiera, S., Schmull, S., Assie, G. et al. (2010) High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. Journal of Clinical Endocrinology and Metabolism, 95, E161E171.
  • 73
    Doghman, M., Cazareth, J., Douguet, D. et al. (2009) Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists. Journal of Clinical Endocrinology and Metabolism, 94, 21782183.
  • 74
    Dallman, M.F. (1984) Control of adrenocortical growth in vivo. Endocrine Research, 10, 213242.
  • 75
    Reincke, M., Mora, P., Beuschlein, F. et al. (1997) Deletion of the adrenocorticotropin receptor gene in human adrenocortical tumors: implications for tumorigenesis. Journal of Clinical Endocrinology and Metabolism, 82, 30543058.
  • 76
    Chida, D., Nakagawa, S., Nagai, S. et al. (2007) Melanocortin 2 receptor is required for adrenal gland development, steroidogenesis, and neonatal gluconeogenesis. Proceedings of the National Academy of Sciences of the United States of America, 104, 1820518210.
  • 77
    Beuschlein, F., Fassnacht, M., Klink, A. et al. (2001) ACTH-receptor expression, regulation and role in adrenocortial tumor formation. European Journal of Endocrinology, 144, 199206.
  • 78
    Parviainen, H., Schrade, A., Kiiveri, S. et al. (2013) Expression of Wnt and TGF-beta pathway components and key adrenal transcription factors in adrenocortical tumors: association to carcinoma aggressiveness. Pathology, Research and Practice, 209, 503509.
  • 79
    Kerbel, R.S. (2008) Tumor angiogenesis. New England Journal of Medicine, 358, 20392049.
  • 80
    Ferrara, N. & Gerber, H.P. (2001) The role of vascular endothelial growth factor in angiogenesis. Acta Haematologica, 106, 148156.
  • 81
    Zacharieva, S., Atanassova, I., Orbetzova, M. et al. (2004) Circulating vascular endothelial growth factor and active renin concentrations and prostaglandin E2 urinary excretion in patients with adrenal tumours. European Journal of Endocrinology, 150, 345349.
  • 82
    de Fraipont, F., El Atifi, M., Gicquel, C. et al. (2000) Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. Journal of Clinical Endocrinology and Metabolism, 85, 47344741.
  • 83
    Kolomecki, K., Stepien, H. & Narebski, J.M. (2000) Vascular endothelial growth factor and basic fibroblast growth factor evaluation in blood serum of patients with hormonally active and inactive adrenal gland tumours. Cytobios, 101, 5564.
  • 84
    Kolomecki, K., Stepien, H., Bartos, M. et al. (2001) Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours. Endocrine Regulations, 35, 916.
  • 85
    Xu, Y.Z., Zhu, Y., Shen, Z.J. et al. (2011) Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy. Endocrine, 40, 445451.
  • 86
    Bernini, G.P., Moretti, A., Bonadio, A.G. et al. (2002) Angiogenesis in human normal and pathologic adrenal cortex. Journal of Clinical Endocrinology and Metabolism, 87, 49614965.
  • 87
    Wortmann, S., Quinkler, M., Ritter, C. et al. (2010) Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. European Journal of Endocrinology, 162, 349356.
  • 88
    Kamio, T., Shigematsu, K., Sou, H. et al. (1990) Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Human Pathology, 21, 277282.
  • 89
    Nakamura, M., Miki, Y., Akahira, J. et al. (2009) An analysis of potential surrogate markers of target-specific therapy in archival materials of adrenocortical carcinoma. Endocrine Pathology, 20, 1723.
  • 90
    Adam, P., Hahner, S., Hartmann, M. et al. (2010) Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Modern Pathology, 23, 15961604.
  • 91
    Quinkler, M., Hahner, S., Wortmann, S. et al. (2008) Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. Journal of Clinical Endocrinology and Metabolism, 93, 20572062.
  • 92
    Berruti, A., Ferrero, A., Sperone, P. et al. (2008) Emerging drugs for adrenocortical carcinoma. Expert Opinion on Emerging Drugs, 13, 497509.
  • 93
    Huang, F., Greer, A., Hurlburt, W. et al. (2009) The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Research, 69, 161170.
  • 94
    West, A.N., Neale, G.A., Pounds, S. et al. (2007) Gene expression profiling of childhood adrenocortical tumors. Cancer Research, 67, 600608.
  • 95
    van Nederveen, F.H. & de Krijger, R.R. (2007) Precursor lesions of the adrenal gland. Pathobiology, 74, 285290.
  • 96
    Chacon, R., Tossen, G., Loria, F.S. et al. (2005) CASE 2. Response in a patient with metastatic adrenal cortical carcinoma with thalidomide. Journal of Clinical Oncology, 23, 15791580.
  • 97
    Zsippai, A., Szabo, D.R., Szabo, P.M. et al. (2011) mRNA and microRNA expression patterns in adrenocortical cancer. American Journal of Cancer Research, 1, 618628.
  • 98
    Patterson, E.E., Holloway, A.K., Weng, J. et al. (2011) MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer, 117, 16301639.
  • 99
    Schmitz, K.J., Helwig, J., Bertram, S. et al. (2011) Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours. Journal of Clinical Pathology, 64, 529535.
  • 100
    Tombol, Z., Szabo, P.M., Molnar, V. et al. (2009) Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocrine-Related Cancer, 16, 895906.
  • 101
    Ladeiro, Y., Couchy, G., Balabaud, C. et al. (2008) MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology, 47, 19551963.
  • 102
    Soon, P.S., Tacon, L.J., Gill, A.J. et al. (2009) miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clinical Cancer Research, 15, 76847692.
  • 103
    Soon, P.S., Gill, A.J., Benn, D.E. et al. (2009) Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocrine-Related Cancer, 16, 573583.
  • 104
    Chabre, O., Libe, R., Assie, G. et al. (2013) Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. Endocrine-Related Cancer, 20, 579594.
  • 105
    Etheridge, A., Lee, I., Hood, L. et al. (2011) Extracellular microRNA: a new source of biomarkers. Mutation Research, 717, 8590.
  • 106
    Singh, P., Soon, P.S., Feige, J.J. et al. (2012) Dysregulation of microRNAs in adrenocortical tumors. Molecular and Cellular Endocrinology, 351, 118128.
  • 107
    Esteller, M. (2008) Epigenetics in cancer. New England Journal of Medicine, 358, 11481159.
  • 108
    Rechache, N.S., Wang, Y., Stevenson, H.S. et al. (2012) DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism, 97, E1004E1013.
  • 109
    Fonseca, A.L., Kugelberg, J., Starker, L.F. et al. (2012) Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Genes Chromosomes Cancer, 51, 949960.
  • 110
    Wortmann, S., Quinkler, M., Ritter, C., et al. (2010) Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. European Journal of Endocrinology, 162, 349356.
  • 111
    Gross, D.J., Munter, G., Bitan, M., et al. (2006) The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocrine-Related Cancer, 13, 535540.
  • 112
    Samnotra, V., Vassilopoulou-Sellin, R. & Fojo, A.T. (2007) A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). Journal of Clinical Oncology.